French drugmaker Sanofi has exercised its option with Selecta Biosciences for second exclusive licence to develop an immunotherapy to treat celiac disease.

In November 2012, Selecta established a strategic global collaboration with Sanofi to develop highly targeted and antigen-specific immunotherapies for life-threatening allergies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the deal, Sanofi received a first exclusive licence to develop an immunotherapy to prevent acute immune responses against a life-threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease.

"This area is constantly evolving, and with partners like Selecta, breakthrough medicines may be within our grasp."

Sanofi biotherapeutics research and development head and vice-president Kurt Stoeckli said: "Sanofi and Selecta are working together to push toward the outer barriers of immunotherapy to deliver innovative solutions to patients.

"This area is constantly evolving, and with partners like Selecta, breakthrough medicines may be within our grasp."

See Also:

The second therapeutic programme will involve in the development of an antigen-specific immunotherapy using Selecta’s synthetic vaccine particle (SVP) technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the deal, Selecta will receive research support from Sanofi, in addition to several pre-clinical, clinical, regulatory and sales milestones up to $300m.

Selecta is also eligible to receive double digit tiered royalties as percentage of product net sales for any commercialised immunotherapy resulting from these efforts with Sanofi.

In October 2014, Selecta and JDRF announced other collaboration with Sanofi to develop new antigen-specific immunotherapies for type 1 diabetes.